
Please try another search
By Investing.com Staff
Shares of DexCom (NASDAQ:DXCM) are 8% higher in early trading Friday after Medicare issued a Local Coverage Decision (LCD) proposal on Thursday for continuous glucose monitors (CGM) that appears to expand coverage to include type 2 basal patients. William Blair analysts said the news effectively doubles the domestic market for CGM.
"While we have expected this at some point over the next year, the announcement comes earlier than expected and is meaningful as the domestic CGM TAM could now more than double in the next several months, moving from 4 million type 1 and type 2 intensive insulin patients to add another 5 million type 2 basal patients," the analysts commented.
The news is also favorable for Abbott Laboratories (NYSE:ABT), which is gaining 1% early Friday.
"... this is an unequivocally positive development for DXCM (and ABT), with seemingly little in the way of proposed patient restrictions on the 3-4M US basal population," Stifel analysts commented on the news. As a results of the news, he raised his price target on Buy-rated DexCom to $120 from $112.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.